Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4 Months Rifampin vs. 9 Months Isoniazid for Latent TB
NCT00931736Phase 3Completed
- Sponsor
- McGill University
- Start
- Aug 2009
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of rifampicin in Tuberculosis (TB) (2 arms), sponsored by McGill University. Primary endpoint: Confirmed active tuberculosis at 28 months. Started Aug 2009; status: completed.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00931736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00931736.